The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...

The Lovelace Heart Hospital is celebrating the new addition of their 1,000th heart device. Called the Watchman, the device ...

Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Boston Scientific Corp.’s OPTION study demonstrated left atrial appendage closure with the Watchman Flx device reduced risk of stroke compared to management with direct oral anticoagulants or warfarin ...

For patients with atrial fibrillation who need protection from stroke and other complications after ablation, left atrial ...

Boston Scientific has reported positive three-year data from the OPTION global trial of the WATCHMAN FLX left atrial appendage closure (LAAC) device in individuals with atrial fibrillation ...

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the ...

The WATCHMAN FLX device showed superior safety with 8.5% major bleeding ... for stroke risk reduction in patients with ...

Left atrial appendage closure is an alternative strategy for stroke prophylaxis, Wazni and colleagues noted. "The safety and ...

Due to the risk of atrial fibrillation recurrence following ... In the trial, approximately 60% of device patients had their WATCHMAN FLX implant 90-180 days following their ablation procedure.